Enantiomer-enantiomer interaction of ifosfamide in the rat

Xenobiotica

Volumn 36, Issue 6, 2006, Pages 535-549

  Lu, H ^a,b,c   Wang, J J ^a,d   Chan, K K ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b GlaxoSmithKline ^*  (United States)

^c GLAXOSMITHKLINE   (United States)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Enantiomeric interaction; Enantioselective metabolism; Ifosfamide

Indexed keywords

IFOSFAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL; CELL SEPARATION; DILUTION; DRUG METABOLISM; ENANTIOMER; GAS CHROMATOGRAPHY; IN VITRO STUDY; LIVER MICROSOME METABOLISM; MALE; MASS SPECTROMETRY; MEAN RESIDENCE TIME; NONHUMAN; RAT; RAT STRAIN; STEREOISOMERISM;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; DRUG INTERACTIONS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; MODELS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 33745173473     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600659122     Document Type: Article

References (27)

1. Bode W, Toet AE, Stolker AA, Van Ginkel LA, Groen K, Wemer J, De Wilt DJ. 1995. Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat. Chirality 7:626-631.
2. Carr RA, Pasutto FM, Foster RT. 1994. Stereospecific evaluation of sotalol pharmacokinetics in rat model: Evidence suggesting an enantiomeric interaction. Biopharmacology and Drug Disposition 15:109-120.
3. Chang TKH, Weber GF, Crespi CL, Waxman DJ. 1993. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research 53:5629-5637.
4. Desta Z, Soukhova N, Morocho AM, Flackhart DA. 2001. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: Major role of CYP3A. Journal of Pharmacology and Experimental Therapy 298:508-520.
5. Farmer PB. 1988. Enantiomers of cyclophosphamide and iphosphamide. Biochemistry and Pharmacology 37:145-148.
6. Gibaldi M. 1993. Stereoselective and isozyme-selective drug interactions. Chirality 5:407-413.
7. Goren MP, Wright RK, Pratt CB, Pell PE. 1986. Dechloroethylation of ifosfamide and neurotoxicity. Lancet ii:1219-1220.
8. Granvil CP, Ducharme J, Leyland-Joes B, Trudeau M, Wainer IW. 1996. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Cancer Chemotherapy and Pharmacology 37:451-456.
9. Granvil CP, Madan A, Sharkawi M, Parkinson A, Wainer IW. 1999. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metabolism and Disposition 27:533-541.
10. Jamali F, Mehvar R, Pasutto FM. 1989. Enantioselective aspects of drug action and disposition: Therapeutic pitfalls. Journal of Pharmacology Science 78:695-715.
11. Lee EJD, Williams KM. 1990. Chirality: Clinical pharmacokinetic and pharmacodynamic considerations. Clinical Pharmacokinetics 18:339-345.
12. Li G, Gong PL, Qiu J, Zeng FD, Klotz U. 1998. Stereoselective steady-state disposition and action of propafenone in Chinese subjects. British Journal of Clinical Pharmacology 46:441-445.
13. Lu H, Wang JJ, Chan KK, Young D. 1998. Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. Drug Metabolism and Disposition 26:476-482.
14. Robinson MA, Mehvar R. 1996. Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: The role of plasma protein binding. Biopharmacology and Drug Disposition 17:577-587.
15. Roy P, Tretyakov O, Wright J, Waxman DJ. 1999. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metabolism and Disposition 27:1309-1318.
16. Tamai I, Ling HY, Timbul SM, Nishikido J, Tsuji A. 1988. Stereospecific absorption and degradation of cephalexin. Journal of Pharmacy and Pharmacology 40:320-324.
17. Wainer IW, Ducharme J, Granville CP. 1996. The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemotherapy and Pharmacology 37:332-336.
18. Wainer IW, Ducharme J, Granvil CP, Trudean M, Leyland-Jones B. 1994b. Ifosfamide stereoselective dechloroethylation and neurotoxicity. Lancet 343:982-983.
19. Wainer IW, Granvil CP, Wang T, Batist G. 1994a. Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model. Cancer Research 54:4393-4397.
20. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH, Idle JR. 1994. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochemistry and Pharmacology 47:1157-1163.
21. Wang JH, Chan KK. 1995a. Identification of new metabolites of ifosfamide in rat urine using ion cluster technique. Journal of Mass Spectrometry 30:675-683.
22. 3-dechloroethylifosfamide, and iphosphoramide mustard in plasma by gas chromatographic-mass spectrometry. Journal of Chromatography B 674:205-217.
23. Wang JJ, Chan KK. 1996. Stereospecific synthesis of tetradeuterated (R)- and (S)-ifosfamide. Journal of Labelled Compounds 38:105-115.
24. Wang JJ, Lu H, Chan KK. 2000. Stereoselective pharmacokinetics of ifosfamide in male and female rats. AAPS Pharmscience 2:1-11.
25. Weber GF, Waxman DJ. 1993. Activation of the anti-cancer drug ifosfamide by rat liver microsomal P450 enzymes. Biochemistry and Pharmacology 45:1685-1694.
26. Yu L, Waxman DJ. 1996. Role of cytochrome P450 in oxazaphosphorine metabolism, Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochrome P450. Drug Metabolism and Disposition 24:1254-1262.
27. Zheng JJ, Chan KK, Muggia F. 1994. Preclinical pharmacokinetics and stability of isophosphoramide mustard. Cancer Chemotherapy and Pharmacology 33:391-398.